Form 8-K Revance Therapeutics, For: Aug 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
William Blair Downgrades Revance Therapeutic (RVNC) to Market Perform
August 12, 2024 11:12 AM EDTWilliam Blair analyst Tim Lugo downgraded Revance Therapeutic (NASDAQ: RVNC) from Outperform to Market Perform.
The analyst comments "Before the market open on Monday, August 12, Revance announced Crown Laboratories, a privately held, global leader in the skincare industry, will commence and... More
Stifel Downgrades Revance Therapeutic (RVNC) to Hold Following Go Private Deal
August 12, 2024 10:07 AM EDTStifel analyst Annabel Samimy downgraded Revance Therapeutic (NASDAQ: RVNC) from Buy to Hold with a price target of $6.66 (from $20.00).
The analyst comments "Surprising to us, RVNC announced this morning its intention to merge with Crown Laboratories, a privately-held, global skincare company for... More
